Chemical Compound Review:
stavudine 1-[(2R,5R)-5-(hydroxymethyl)- 2,5...
Synonyms:
Zerit, BMY-27857, BMY27857, BMY 27857, d4T, ...
Pedersen,
Colonno,
Ferchal,
Griffith,
Bernasconi,
Walker,
Ferchal,
Molina,
Caron,
McComsey,
Jurriaans,
Vernazza,
Mathiesen,
Furrer,
Pellegrin,
Mellors,
Bucher,
Capeau,
Portegies,
Edwards,
Gaur,
Sambeat,
Chêuc,
Rodriguez,
Pérez,
Gerstoft,
Lombès,
Boonyaprawit,
Journot,
Sombardier,
Cotte,
Battegay,
Decazes,
Ordoñez,
Debord,
Roos,
Rancinan,
Arnold,
Schinazi,
Wainberg,
Weber,
Madelaine,
Rickenbach,
Katzenstein,
Calvez,
DiCola,
Foudraine,
Chetchotisakd,
Mootsikapun,
Nielsen,
de Wolf,
Reiss,
John,
Young,
Lange,
Lundgren,
Obel,
Anunnatsiri,
Kirk,
Vázquez,
Burger,
Kornprobst,
Maas,
Arenas-Pinto,
Friedland,
Tarr,
Das,
Pottage,
González,
Grant,
Hirschel,
Weverling,
Lagathu,
Ashraf,
Yau,
Lin,
Soriano,
Weller,
Miedema,
Shepp,
Sha,
Auclair,
Fitzgibbon,
Røge,
Nahass,
Domingo,
Hoetelmans,
- Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Foudraine, N.A., Hoetelmans, R.M., Lange, J.M., de Wolf, F., van Benthem, B.H., Maas, J.J., Keet, I.P., Portegies, P. Lancet (1998)
- Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group. Spruance, S.L., Pavia, A.T., Mellors, J.W., Murphy, R., Gathe, J., Stool, E., Jemsek, J.G., Dellamonica, P., Cross, A., Dunkle, L. Ann. Intern. Med. (1997)
- Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Miller, K.D., Cameron, M., Wood, L.V., Dalakas, M.C., Kovacs, J.A. Ann. Intern. Med. (2000)
- Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-1 infection. Katlama, C., Valantin, M.A., Matheron, S., Coutellier, A., Calvez, V., Descamps, D., Longuet, C., Bonmarchand, M., Tubiana, R., De Sa, M., Lancar, R., Agut, H., Brun-Vezinet, F., Costagliola, D. Ann. Intern. Med. (1998)
- Fat distribution and metabolic abnormalities in HIV-infected patients on first combination antiretroviral therapy including stavudine or zidovudine: role of physical activity as a protective factor. Domingo, P., Sambeat, M.A., Pérez, A., Ordoñez, J., Rodriguez, J., Vázquez, G. Antivir. Ther. (Lond.) (2003)
- Self-perception of body changes in persons living with HIV/AIDS: prevalence and associated factors. Santos, C.P., Felipe, Y.X., Braga, P.E., Ramos, D., Lima, R.O., Segurado, A.C. AIDS (2005)
- Risk of HIV dementia and opportunistic brain disease in AIDS and zidovudine therapy. Baldeweg, T., Catalan, J., Gazzard, B.G. J. Neurol. Neurosurg. Psychiatr. (1998)
- Lactic acidosis in HIV infected patients: a systematic review of published cases. Arenas-Pinto, A., Grant, A.D., Edwards, S., Weller, I.V. Sexually transmitted infections. (2003)
- Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. Carr, A., Workman, C., Smith, D.E., Hoy, J., Hudson, J., Doong, N., Martin, A., Amin, J., Freund, J., Law, M., Cooper, D.A. JAMA (2002)
- Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Reijers, M.H., Weverling, G.J., Jurriaans, S., Wit, F.W., Weigel, H.M., Ten Kate, R.W., Mulder, J.W., Frissen, P.H., van Leeuwen, R., Reiss, P., Schuitemaker, H., de Wolf, F., Lange, J.M. Lancet (1998)
- Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients. Molina, J.M., Chêuc, G., Ferchal, F., Journot, V., Pellegrin, I., Sombardier, M.N., Rancinan, C., Cotte, L., Madelaine, I., Debord, T., Decazes, J.M. Antivir. Ther. (Lond.) (1999)
- Short-term efficacy and safety of stavudine in pretreated HIV-infected patients. Villalba, N., Soriano, V., Gómez-Cano, M., Castilla, J., Mas, A., González-Lahoz, J. Antivir. Ther. (Lond.) (1997)
- Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial. Foudraine, N.A., Jurriaans, S., Weverling, G.J., Burger, D.M., Hoetelmans, R.M., Roos, M.T., Maas, J., Miedema, F., Reiss, P., Portegies, P., de Wolf, F., Lange, J.M. Antivir. Ther. (Lond.) (2001)
- Letter. In vitro phenotypic susceptibility to nucleoside reverse transcriptase inhibitors of HIV-2 isolates with the Q151M mutation in the reverse transcriptase gene. Damond, F., Collin, G., Matheron, S., Peytavin, G., Campa, P., Delarue, S., Taieb, A., Bénard, A., Chêne, G., Brun-Vézinet, F., Descamps, D. Antivir. Ther. (Lond.) (2005)
- Genotypic and phenotypic resistance to stavudine after long-term monotherapy. BMS-020 Spanish Study Group. Holguín, A., Dietrich, U., Immelmann, A., Soriano, V. Antivir. Ther. (Lond.) (1998)
- Anti-HIV antiviral activity of stavudine in a thymidine kinase-deficient cellular line. Turriziani, O., Simeoni, E., Dianzani, F., Antonelli, G. Antivir. Ther. (Lond.) (1998)
- Stavudine resistance: an update on susceptibility following prolonged therapy. Lin, P.F., González, C.J., Griffith, B., Friedland, G., Calvez, V., Ferchal, F., Schinazi, R.F., Shepp, D.H., Ashraf, A.B., Wainberg, M.A., Soriano, V., Mellors, J.W., Colonno, R.J. Antivir. Ther. (Lond.) (1999)
- HIV-1 reverse transcriptase mutations found in a drug-experienced patient confer reduced susceptibility to multiple nucleoside reverse transcriptase inhibitors. Fitzgibbon, J.E., DiCola, B., Arnold, E., Das, K., Sha, B.E., Pottage, J.C., Nahass, R., Gaur, S., John, J.F. Antivir. Ther. (Lond.) (2001)
- Diminished HIV-1 sensitivity to stavudine in patients on prolonged therapy occurs only at low levels and cannot be attributed to any single amino acid substitution in reverse transcriptase. Salomon, H., Montaner, J.S., Belmonte, A., Wainberg, M.A. Antivir. Ther. (Lond.) (1998)
- Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Nolan, D., Hammond, E., James, I., McKinnon, E., Mallal, S. Antivir. Ther. (Lond.) (2003)
- Selection of a T-cell line resistant to stavudine and zidovudine by prolonged treatment with stavudine. Turriziani, O., Scognolari, C., Bambacioni, F., Bellomi, F., Focher, F., Gentile, M., Antonelli, G. Antivir. Ther. (Lond.) (2002)
- Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro. Lagathu, C., Bastard, J.P., Auclair, M., Maachi, M., Kornprobst, M., Capeau, J., Caron, M. Antivir. Ther. (Lond.) (2004)
- K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Røge, B.T., Katzenstein, T.L., Obel, N., Nielsen, H., Kirk, O., Pedersen, C., Mathiesen, L., Lundgren, J., Gerstoft, J. Antivir. Ther. (Lond.) (2003)
- Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes. Mootsikapun, P., Chetchotisakd, P., Anunnatsiri, S., Boonyaprawit, P. Antivir. Ther. (Lond.) (2005)
- Asymptomatic hyperlactataemia: predictive value, natural history and correlates. McComsey, G.A., Yau, L. Antivir. Ther. (Lond.) (2004)
- Effects of zidovudine, stavudine and beta-aminoisobutyric acid on lipid homeostasis in mice: possible role in human fat wasting. Maisonneuve, C., Igoudjil, A., Begriche, K., Lettéron, P., Guimont, M.C., Bastin, J., Laigneau, J.P., Pessayre, D., Fromenty, B. Antivir. Ther. (Lond.) (2004)
- Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors. Jones, S.P., Janneh, O., Back, D.J., Pirmohamed, M. Antivir. Ther. (Lond.) (2005)
- Pyrimidine nucleoside depletion sensitizes to the mitochondrial hepatotoxicity of the reverse transcriptase inhibitor stavudine. Setzer, B., Lebrecht, D., Walker, U.A. Am. J. Pathol. (2008)
- Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients. Pace, C.S., Martin, A.M., Hammond, E.L., Mamotte, C.D., Nolan, D.A., Mallal, S.A. Antivir. Ther. (Lond.) (2003)
- The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro. Caron, M., Auclair, M., Lagathu, C., Lombès, A., Walker, U.A., Kornprobst, M., Capeau, J. AIDS (2004)
- Effect of the combination of interferon-alpha and stavudine on Friend virus infections in (B10.A x A.By)F1 mice. Sidwell, R.W., Warren, R.P., Okleberry, K., Burger, R.A., Morrey, J.D. J. Infect. Dis. (1995)
- Low plasma level of adiponectin is associated with stavudine treatment and lipodystrophy in HIV-infected patients. Lindegaard, B., Keller, P., Bruunsgaard, H., Gerstoft, J., Pedersen, B.K. Clin. Exp. Immunol. (2004)
- Antiretroviral activity of stavudine (2',3'-didehydro-3'-deoxythymidine, D4T). Riddler, S.A., Anderson, R.E., Mellors, J.W. Antiviral Res. (1995)
- Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study. Young, J., Rickenbach, M., Weber, R., Furrer, H., Bernasconi, E., Hirschel, B., Tarr, P.E., Vernazza, P., Battegay, M., Bucher, H.C. Antivir. Ther. (Lond.) (2005)
- Didanosine plus stavudine with or without hydroxyurea in HIV-1-infected patients: 1 year follow-up. Swiss HIV Cohort Study. Rutschmann, O.T., Opravil, M., Iten, A., Malinverni, R., Vernazza, P.L., Bucher, H., Bernasconi, E., Perrin, L.H., Yerly, S., Hirschel, B. Antivir. Ther. (Lond.) (1998)